AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
bioAffinity Technologies, Inc. (NASDAQ:BIAF)
0.25 USD
+0.002 0.807%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.248 |
|---|---|
| Change | +0.002 0.807% |
| 52 W H/L (in USD) | 3.620/0.919 |
| EBITDA (in USD) | -8.035M |
| PE Ratio | -- |
| Volume | 184668 |
| Diluted Eps TTM | -0.91 |
| Total Assets (in USD) | 8.222M |
|---|---|
| Total Liabilities (in USD) | 3.366M |
| Revenue TTM (in USD) | 7.316M |
| Cash (in USD) | 2.822M |
| Market Cap (in USD) | 19.810 M |
| Revenue Per Share TTM | 0.744 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
22211 West Interstate 10, San Antonio, TX, United States, 78257
210 698 5334
Employees: 75
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Maria Zannes J.D. | Founder, Pres, CEO & Director | 1956 |
| 2. | Dr. Vivienne I. Rebel M.D., Ph.D. | Exec. VP and Chief Medical & Science Officer | 1965 |
| 3. | Mr. Michael Edwards CPA, M.B.A. | Chief Financial Officer | 1967 |
| 4. | Mr. Xavier T. Reveles M.S. | VP of Operations | NA |
| 5. | Mr. Timothy P. Zannes J.D. | Exec. VP, Sec. & Gen. Counsel | 1953 |
| 6. | Dr. William Bauta Ph.D. | Sr. VP of Therapeutics | NA |
| 7. | Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 1946 |
| 8. | Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 1956 |
| 9. | Mr. Michael Dougherty C.P.A., M.B.A. | VP & CFO | 1979 |
| 10. | Mr. Xavier T. Reveles M.S. | Chief Operating Officer | 1970 |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
+5.745 1.421% | 402.22 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
+3.860 1.955% | 196.895 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
+1.550 1.318% | 117.11 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
-0.220 0.042% | 531.69 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -7.916M | -8.152M | -6.324M | -7.266M | -3.304M |
| Minority Interest | - | - | - | - | - |
| Net Income | -7.937M | -8.154M | -6.326M | -7.269M | -3.307M |
| Selling General Administrative | 6.791M | 2.727M | 0.881M | 0.994M | - |
| Gross Profit | 0.542M | 0.004M | -0.005M | -0.022M | -0.04M |
| Reconciled Depreciation | 0.108M | 0.01M | 0.005M | 0.022M | - |
| Ebit | -7.973M | -4.011M | -2.207M | -2.604M | -3.092M |
| Ebitda | -7.724M | -5.821M | -1.477M | -6.862M | -3.052M |
| Depreciation And Amortization | 0.25M | -1.81M | 0.73M | -4.257M | 0.04M |
| Operating Income | -7.973M | -4.011M | -2.207M | -2.604M | -3.092M |
| Other Operating Expenses | 10.506M | 4.016M | 2.207M | 2.604M | 3.092M |
| Interest Expense | 0.037M | 2.533M | 1.002M | 0.382M | 0.215M |
| Tax Provision | 0.019M | 0.002M | 0.002M | 0.003M | - |
| Interest Income | 0.148M | 0.047M | 0M | 0.001M | - |
| Net Interest Income | 0.047M | -2.486M | -1.001M | -0.381M | - |
| Income Tax Expense | 0.021M | 0.002M | 0.002M | 0.003M | 0.003M |
| Total Revenue | 2.532M | 0.005M | 0.001M | 0M | - |
| Total Operating Expenses | 8.515M | 4.015M | 2.207M | 2.604M | 3.052M |
| Cost Of Revenue | 1.99M | 0M | 0.005M | 0.022M | 0.04M |
| Total Other Income Expense Net | 0.057M | -4.141M | -4.118M | -4.662M | -0.212M |
| Net Income From Continuing Ops | -7.238M | -8.154M | -6.326M | -7.269M | - |
| Net Income Applicable To Common Shares | - | - | -6.326M | -7.269M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 8.222M | 12.182M | 1.453M | 0.146M | 0.659M |
| Intangible Assets | 0.833M | - | - | - | - |
| Other Current Assets | 0.321M | 0.12M | 0.004M | 0.006M | 0.037M |
| Total Liab | 3.366M | 1.139M | 17.244M | 15.218M | 4.694M |
| Total Stockholder Equity | 4.855M | 11.043M | -15.791M | -15.073M | -4.036M |
| Other Current Liab | 1.15M | 0.542M | 1.605M | 0.976M | 0.58M |
| Common Stock | 0.066M | 0.059M | 0.019M | 0.019M | 0.019M |
| Capital Stock | 0.066M | 0.059M | 0.019M | 0.019M | - |
| Retained Earnings | -44.604M | -36.667M | -28.513M | -22.187M | -14.918M |
| Good Will | 1.404M | - | - | - | - |
| Other Assets | - | - | 0.01M | 0.018M | - |
| Cash | 2.822M | 11.414M | 1.361M | 0.083M | 0.578M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.248M | 1.139M | 13.04M | 11.121M | 4.694M |
| Current Deferred Revenue | 0.033M | - | - | - | - |
| Net Debt | -1.243M | -11.162M | 10.004M | 9.924M | 3.433M |
| Short Term Debt | 0.46M | 0.252M | 11.204M | 9.953M | 4.011M |
| Short Long Term Debt | - | 0.252M | 11.204M | 9.953M | - |
| Short Long Term Debt Total | 1.579M | 0.252M | 11.364M | 10.007M | 4.011M |
| Other Stockholder Equity | 49.394M | -12134.473M | 12.704M | 7.095M | 6.838M |
| Property Plant Equipment | - | - | 0.005M | 0.009M | - |
| Total Current Assets | 3.973M | 11.962M | 1.438M | 0.119M | 0.618M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.812M | 0.01M | 0.002M | 0.002M | 0.002M |
| Long Term Debt | - | - | 0.16M | 0.053M | - |
| Inventory | 0.018M | 0.006M | 0.072M | 0.028M | - |
| Accounts Payable | 0.605M | 0.345M | 0.23M | 0.191M | 0.103M |
| Accumulated Other Comprehensive Income | - | - | - | - | -0.019M |
| Non Currrent Assets Other | 0.016M | 0.006M | 0.01M | 0.018M | 0.013M |
| Non Current Assets Total | 4.249M | 0.22M | 0.015M | 0.027M | 0.041M |
| Capital Lease Obligations | 1.579M | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -2.443M | -0.22M | 0M | -0.003M | - |
| Total Cashflows From Investing Activities | - | - | - | -0.003M | - |
| Total Cash From Financing Activities | -0.345M | 14.344M | 3.327M | 1.715M | 2.335M |
| Net Income | -7.937M | -8.154M | -6.326M | -7.269M | -3.307M |
| Change In Cash | -8.592M | 10.053M | 1.278M | -0.495M | -0.167M |
| Begin Period Cash Flow | 11.414M | 1.361M | 0.083M | 0.578M | 0.745M |
| End Period Cash Flow | 2.822M | 11.414M | 1.361M | 0.083M | 0.578M |
| Total Cash From Operating Activities | -6.038M | -4.071M | -2.049M | -2.208M | -2.49M |
| Depreciation | 0.25M | 0.01M | 0.005M | 0.022M | 0.04M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | 0M | - | - | - |
| Change To Inventory | -0.013M | -0.006M | 0M | - | - |
| Sale Purchase Of Stock | - | -0M | - | - | - |
| Other Cashflows From Financing Activities | -0.345M | 9.012M | 6.834M | 3.43M | -0.011M |
| Capital Expenditures | 0.023M | 0.22M | 0M | 0.003M | 0.011M |
| Change In Working Capital | 0.901M | 0.114M | 0.633M | 0.483M | 0.322M |
| Other Non Cash Items | 0.964M | 3.71M | -0.244M | 4.281M | 0.575M |
| Free Cash Flow | -6.061M | -4.291M | -2.049M | -2.211M | -2.502M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 220227 |
| 2. | Fidelity Extended Market Index | 7 months ago | 47313 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 40642 |
| 4. | Fidelity Total Market Index | 7 months ago | 13704 |
| 5. | Fidelity Series Total Market Index | 7 months ago | 11541 |
| 6. | Fidelity Nasdaq Composite Index | 7 months ago | 9407 |
| 7. | NT Ext Equity Mkt Idx Fd - NL | 8 months ago | 9402 |
| 8. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 8 months ago | 7575 |
| 9. | Spartan Extended Market Index Pool E | 7 months ago | 6736 |
| 10. | NT Ext Equity Mkt Idx Fd - L | 8 months ago | 4260 |
| 11. | Northern Trust Extended Eq Market Idx | 8 months ago | 4260 |
| 12. | Spartan Total Market Index Pool E | 7 months ago | 2188 |
| 13. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 8 months ago | 657 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 8 months ago | 260869 |
| 2. | Geode Capital Management, LLC | 8 months ago | 87181 |
| 3. | CapTrust Financial Advisors | 8 months ago | 27885 |
| 4. | Sheaff Brock Investment Advisors, LLC | 8 months ago | 20000 |
| 5. | State Street Corp | 8 months ago | 17600 |
| 6. | Northern Trust Corp | 8 months ago | 13662 |
| 7. | Creative Planning Inc | 8 months ago | 12095 |
| 8. | XTX Topco Ltd | 8 months ago | 11264 |
| 9. | IFP Advisors, LLC | 11 months ago | 10000 |
| 10. | Morgan Stanley - Brokerage Accounts | 8 months ago | 4961 |
| 11. | Tower Research Capital LLC | 8 months ago | 2085 |
| 12. | JPMorgan Chase & Co | 8 months ago | 21 |
| 13. | Ground Swell Capital, LLC | 8 months ago | 0 |
| 14. | Wells Fargo & Co | 11 months ago | 0 |
| 15. | UBS Group AG | 8 months ago | 0 |
| 16. | Renaissance Technologies Corp | 8 months ago | 0 |
| 17. | Qube Research & Technologies | 8 months ago | 0 |
| 18. | Cypress Capital, LLC | 8 months ago | 0 |
| 19. | Bank of America Corp | 8 months ago | 67 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...